Trials / Not Yet Recruiting
Not Yet RecruitingNCT07424430
Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes
Real-world Canadian Retrospective Study Evaluating Longitudinal SEMAglutide Use on Cardio-Kidney-Metabolic Outcomes
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 400 (estimated)
- Sponsor
- LMC Diabetes & Endocrinology Ltd. · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to better understand the real-world effectiveness of semaglutide use on cardio-kidney-metabolic outcomes among adults with T2D and adults with obesity (without diabetes mellitus). This is a retrospective longitudinal analysis using the LMC Diabetes Registry. The primary outcome of the study is to evaluate the change in HbA1c between baseline to 3 years of follow-up among adults with T2D who initiated semaglutide compared to adults with T2D who initiated other AHAs, including sulfonylurea, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter-2 inhibitors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Semaglutide (SEMA) | participants who initiate semaglutide |
Timeline
- Start date
- 2026-03-01
- Primary completion
- 2026-04-01
- Completion
- 2026-05-01
- First posted
- 2026-02-20
- Last updated
- 2026-02-20
Source: ClinicalTrials.gov record NCT07424430. Inclusion in this directory is not an endorsement.